Alteon Announces Investor Update Conference Call Monday, December 20, 2004, 4:00 P.M. Eastern Time
December 14 2004 - 8:27AM
PR Newswire (US)
Alteon Announces Investor Update Conference Call Monday, December
20, 2004, 4:00 P.M. Eastern Time --- Conference Call to be Webcast
--- PARSIPPANY, N.J., Dec. 14 /PRNewswire-FirstCall/ -- Alteon Inc.
(AMEX:ALT) announced that it will hold a regularly scheduled
investor update conference call on Monday, December 20, 2004 at
4:00 p.m. ET. Anyone interested in participating in the live
conference call should RSVP to Nancy Regan at . There will be a
full question and answer period during the call. The call-in
telephone number for the conference call will be 1-800-967-7184.
International participants may call +719-457-2633. Participants
should call approximately 5-10 minutes before 4:00 p.m. In
addition, the conference call will be accessible through a webcast
on the company website, http://www.alteon.com/ in the Investor
Relations section, and a digital rebroadcast will be available
through December 27, 2004 at 11:59 P.M. by dialing 1-888-203-1112,
passcode 979982 for domestic callers and +719-457-0820, passcode
979982 for international callers. About Alteon Alteon is developing
several new classes of drugs that have shown the potential to
reverse or slow down diseases of aging and complications of
diabetes. These compounds have an impact on a fundamental
pathological process caused by the progressive formation of
protein-glucose complexes called Advanced Glycation End-products
(A.G.E.s). The formation and crosslinking of A.G.E.s lead to a loss
of flexibility and function in body tissues and organs and have
been shown to be a causative factor in many age-related diseases
and diabetic complications. Alteon has created a library of novel
classes of compounds targeting the A.G.E. pathway. Alteon's lead
compound alagebrium chloride (formerly ALT-711), the only A.G.E.
Crosslink Breaker in advanced human testing, has demonstrated
safety and efficacy in several Phase 2 trials and is actively being
developed for systolic hypertension and heart failure. Over 1200
patients have been involved in alagebrium's human clinical trials
to date, of whom approximately 900 have received active compound.
Ongoing clinical trials include the phase 2b systolic hypertension
trial, SPECTRA (Systolic Pressure Efficacy and Safety Trial of
Alagebrium), and the phase 2a heart failure trial, PEDESTAL
(Patients with Impaired Ejection Fraction and Diastolic
Dysfunction: Efficacy and Safety Trial of ALagebrium), as well as a
third trial exploring mechanism of action in endothelial
dysfunction. For more detailed information about alagebrium, please
visit the scientific publications section of the Alteon website,
http://www.alteon.com/. Any statements contained in this press
release that relate to future plans, events or performance are
forward-looking statements that involve risks and uncertainties
including, but not limited to, those relating to technology and
product development (including the possibility that early clinical
trial results may not be predictive of results that will be
obtained in large-scale testing or that any clinical trials will
not demonstrate sufficient safety and efficacy to obtain requisite
approvals or will not result in marketable products), regulatory
approval processes, intellectual property rights and litigation,
competitive products, ability to obtain financing, and other risks
identified in Alteon's filings with the Securities and Exchange
Commission. The information contained in this press release is
accurate as of the date indicated. Actual results, events or
performance may differ materially. Alteon undertakes no obligation
to publicly release the result of any revision to these
forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. DATASOURCE: Alteon, Inc. CONTACT: Susan M.
Pietropaolo, Director, Corporate Communications & Investor
Relations of Alteon, Inc., +1-201-818-5537 Web site:
http://www.alteon.com/
Copyright
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Ishares Diversified Alternatives Trust (American Stock Exchange): 0 recent articles
More Alteon , News Articles